Therapeutics News and Research

RSS

Assessing the potential of IFNa subtypes in suppressing SARS-CoV-2

A recent study analyzes IFNa subtypes for their therapeutic potential against SARS-CoV-2 and identified the underlying immune signatures and mechanisms.

3 Mar 2022

Fortis Life Sciences acquires Abcore, a leader in nanobody technologies

Fortis Life Sciences has acquired Abcore, a San Diego, California, USA based antibody discovery platform specializing in nanobody technology. With the addition of Abcore, Fortis extends its capabilities into the antibody discovery market serving biopharma customers developing antibody and nanobody-based therapeutics.

From Fortis Life Sciences 3 Mar 2022

UH researcher receives $2 million to develop drugs for traditionally undruggable targets in cancer

With a $2 million recruitment grant from the Cancer Prevention and Research Institute of Texas, a University of Houston researcher is setting up a lab to develop drugs that will work on traditionally undruggable targets in cancer.

2 Mar 2022

Antigenic differences between Omicron BA.1 and BA.2 SARS-CoV-2 variants

A new study identifies the antigenic differences that exist between the Omicron BA.2 and BA.1 variants.

2 Mar 2022

Intensive treatment for patients with Crohn's disease found to be safe

Intensive treatment for patients with Crohn's disease showed no safety differences compared to the current standard of care, according to a trial published in the journal Gastroenterology.

1 Mar 2022

Government to revoke regulations making COVID-19 vaccination as a condition of deployment

Regulations making COVID-19 vaccination a condition of deployment in health and social care will be revoked on Tuesday 15 March, the Health and Social Care Secretary has confirmed today (Tuesday 1 March).

1 Mar 2022

Study reveals how the immune system can be triggered to attack cancer cells

New research from the University of East Anglia and Quadram Institute reveals how our immune system can be triggered to attack cancer cells.

1 Mar 2022

Triple antibody cocktail is a promising candidate for immunotherapy against SARS-CoV-2 variants of concern

Researchers generated a panel of bnAbs against SARS-CoV, SARS-CoV-2, and its variant VOCs, including Omicron from sequentially immunized mice.

28 Feb 2022

Noncovalent protease inhibitors against SARS-CoV-2 and other coronaviruses

In a new study published in ACS Infectious Diseases journal, scientists biochemically and structurally evaluated the PLpro from a subgroup 2b bat coronavirus, BtSCoV-Rf1.2004, to identify unique structural features or enzymatic biases of the subgroup 2b.

28 Feb 2022

Altered microbiomes in SARS-CoV-2 infection pose threat of antibiotic resistance

A new study discusses changes in the microbiota of various parts of the body with SARS-CoV-2 infection.

27 Feb 2022

Harvard’s new kidney engineering technology licensed to San Diego-based Trestle Biotherapeutics

A newly launched startup is building upon innovations developed over several years at the Wyss Institute for Biologically Inspired Engineering at Harvard University, Harvard John A. Paulson School of Engineering & Applied Sciences (SEAS), and Brigham and Women’s Hospital (Brigham) to engineer functional kidney tissue for renal repair and replacement therapy.

25 Feb 2022

Study reveals how the immune system can be triggered to fight cancer cells

New research from the University of East Anglia and Quadram Institute reveals how our immune system can be triggered to attack cancer cells.

25 Feb 2022

Protective immunity signatures provided by convalescent plasma for the development of COVID-19 antibody therapeutics

Researchers conducted a comprehensive and systematic analysis of functional SARS-CoV-2 antibody profiles in a controlled randomized trial of severe COVID-19 hospitalized individuals treated with COVID-19 CCP.

25 Feb 2022

Application of various nanoparticle-capsulated siRNA as therapeutics for SARS-CoV-2 infection

In a review published in the International Journal of Molecular Sciences, researchers have been reviewing the use of siRNAs to target coronaviruses.

25 Feb 2022

Mapping cells to understand vascular disease

In this interview, we speak to Dr. Ethan Winkler and Dr. Tomasz Nowakowski about their latest research which illustrated the interplay between vascular and immune cells that contributes to brain hemorrhage.

25 Feb 2022

Researchers analyze the use of palliative care for hospitalized patients with both AKI and COVID-19

Acute kidney injury (AKI) is a common complication of COVID-19 and is associated with a higher risk of death. A new study published in CJASN has examined the use of palliative care in patients with COVID-19 and AKI.

24 Feb 2022

Phase I clinical trial evaluates AI-discovered first anti-fibrotic small molecule inhibitor

Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that it has dosed multiple healthy volunteers in Phase I clinical trial evaluating ISM001-055, the first anti-fibrotic small molecule inhibitor generated by Insilico's AI-powered drug discovery platform for idiopathic pulmonary fibrosis (IPF).

24 Feb 2022

Therapeutics News and Research

Assessing the potential of IFNa subtypes in suppressing SARS-CoV-2

Fortis Life Sciences acquires Abcore, a leader in nanobody technologies

UH researcher receives $2 million to develop drugs for traditionally undruggable targets in cancer

Antigenic differences between Omicron BA.1 and BA.2 SARS-CoV-2 variants

Intensive treatment for patients with Crohn's disease found to be safe

Government to revoke regulations making COVID-19 vaccination as a condition of deployment

Study reveals how the immune system can be triggered to attack cancer cells

Triple antibody cocktail is a promising candidate for immunotherapy against SARS-CoV-2 variants of concern

Noncovalent protease inhibitors against SARS-CoV-2 and other coronaviruses

Altered microbiomes in SARS-CoV-2 infection pose threat of antibiotic resistance

Harvard’s new kidney engineering technology licensed to San Diego-based Trestle Biotherapeutics

Study reveals how the immune system can be triggered to fight cancer cells

Protective immunity signatures provided by convalescent plasma for the development of COVID-19 antibody therapeutics

Application of various nanoparticle-capsulated siRNA as therapeutics for SARS-CoV-2 infection

Mapping cells to understand vascular disease

Researchers analyze the use of palliative care for hospitalized patients with both AKI and COVID-19

Phase I clinical trial evaluates AI-discovered first anti-fibrotic small molecule inhibitor

Scientists uncover new role of chromatin-modulatory enzyme during cancer development

Study explores the boosting of SARS-CoV-2 adenovirus vaccine-induced immunity by capsid decoration

Discovery could lead to new treatment approach for people with alcohol-associated liver disease

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News